Kazia Prices $40M ADS Offering With Warrants, Up to $120M Total
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (5.1× avg).
Summary
Kazia priced its public offering at $15.50 per ADS with warrants, raising $40M upfront and up to $120M if warrants are exercised. The offering includes Series A warrants exercisable at $17.825 and Series B at $19.375, both tied to clinical data readouts. This follows yesterday's 100% clinical benefit announcement in TNBC, which drove the stock up before a 17% drop on the offering news. The pricing is below the current market price of $14.21, indicating dilution pressure. Proceeds will fund paxalisib development in breast cancer and other indications. The offering is expected to close August 31, 2026.
At the time of this announcement, KZIA was trading at $14.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.1M. The 52-week trading range was $4.86 to $17.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.